Evidence, by indication

Indication Map

A careful, indication-by-indication view of where ibogaine has been studied in humans, what the evidence can and cannot show, and why safety remains inseparable from interpretation.

How to read this page

A map is not a treatment claim.

This page separates studied indications from established care. It does not present ibogaine as an approved treatment, does not make clinical recommendations, and does not offer access information. Instead, it describes the kinds of human research reported, the outcomes typically measured, and the limits that keep many conclusions provisional.

For a broader orientation to the topic, the Ibogaine Evidence Hub’s central overview frames the same evidence-first approach. Definitions also matter: substance use disorder is a clinical umbrella that includes patterns of impaired control, continued use despite harm, and other criteria; a research label alone does not establish a diagnosis or a suitable course of care.

The question is not simply whether a signal exists. It is how strong the signal is, how it was measured, who was studied, and what risks traveled with it.

Indication-by-indication

The current map

Ratings describe the quality and maturity of reported human evidence, not efficacy for an individual. “Promising” still falls well short of definitive proof.

Promising, nondefinitive

Opioid use disorder

Definition: A substance use disorder involving opioid use, commonly assessed through use patterns, withdrawal, craving, retention, and related functioning.
Human evidence: Small observational cohorts, open-label studies, retrospective reports, and follow-up surveys have reported changes in withdrawal, self-reported opioid use, and time to relapse. Samples are generally limited and comparison groups are often absent.
Key safety concerns: QT-interval prolongation, potentially dangerous arrhythmias, concurrent opioid and other medication exposure, electrolyte disturbance, and medical comorbidity are central concerns.
Research gaps: Controlled trials, transparent attrition reporting, standardized endpoints, longer follow-up, and careful accounting for co-interventions remain needed.

Early / very weak

Stimulant use disorder

Definition: Problematic use of stimulants such as cocaine or methamphetamine, with outcomes commonly centered on use, craving, psychiatric symptoms, and functioning.
Human evidence: Published human material is sparse and tends to combine substances or rely on uncontrolled observations. It does not provide a firm indication-specific estimate of benefit.
Key safety concerns: Cardiovascular strain, psychiatric instability, polysubstance exposure, and drug interactions can complicate interpretation and raise risk concerns.
Research gaps: Separate stimulant-specific samples, verified use outcomes, prospective safety monitoring, and controlled comparisons are required.

Early / very weak

Alcohol use disorder

Definition: A substance use disorder involving alcohol, often studied through drinking days, heavy-drinking days, craving, withdrawal, and alcohol-related harms.
Human evidence: Human reports are limited and heterogeneous, with small or uncontrolled designs. Existing work does not establish an approved role or a reliable effect estimate.
Key safety concerns: Withdrawal-related complications, liver disease, electrolyte abnormalities, psychiatric symptoms, and concurrent medications may all be relevant to risk.
Research gaps: Clearly defined alcohol-specific cohorts, objective outcome measures, adverse-event reporting, and longer follow-up are needed.

None to very weak

Nicotine dependence

Definition: A pattern of dependence on nicotine, often measured through abstinence, cigarettes used, craving, and withdrawal.
Human evidence: Reports and early exploratory work exist, but the evidence base is limited and does not support a confident conclusion about durable abstinence or comparative benefit.
Key safety concerns: Cardiac risk remains relevant even when the target substance is nicotine; existing health conditions and interacting drugs cannot be assumed away.
Research gaps: Biochemically verified abstinence, comparison groups, pre-specified follow-up periods, and systematic safety reporting are absent or insufficient.

Quiet natural landscape supporting a discussion of evidence limits and safety — Study design, follow-up, and adverse-event reporting determine what a result can mean.

Beyond substance-use indications

Behavioral health questions remain largely unresolved.

Ibogaine has sometimes been discussed in relation to trauma-related symptoms, depression, anxiety, and other behavioral health concerns. The available human literature in these areas is generally preliminary, uncontrolled, mixed with substance-use samples, or not sufficient to establish an indication. A change in symptoms observed in a small cohort cannot distinguish drug effects from selection, setting, expectancy, concurrent support, or natural variation.

Mental health risk also deserves direct attention. People with a history of psychosis, mania, severe mood instability, or complex medication regimens may face particular concerns; the risk and consideration guide keeps cardiac, psychiatric, and interaction issues in the foreground. In the United States, the FDA’s drug safety information is a useful reminder that safety evaluation and approval are distinct processes, and neither should be inferred from anecdotal outcomes.

Evidence discipline

Why the rating is usually lower than the headline.

Many ibogaine studies are exploratory: they may use open-label designs, self-reported outcomes, short follow-up, small samples, or cohorts with more than one substance-use condition. These designs can identify a question worth testing, but they cannot reliably isolate cause and effect. Randomization, blinding where feasible, transparent losses to follow-up, and appropriate comparators help reduce bias.

Safety cannot be treated as a side note. Ibogaine has been associated with QT-interval prolongation, a change that can be relevant to serious rhythm risk. Reported outcomes need to be read alongside medication exposure, cardiac history, electrolyte status, withdrawal state, and adverse-event capture. A favorable average outcome does not erase a rare but severe event.

Quiet comparison

What stronger research would clarify

Across indications, the same methodological questions recur: who was included, what was compared, how outcomes were verified, and what happened over time.

Endpoints

Pre-specified outcomes could distinguish short-term withdrawal or symptom changes from sustained changes in substance use, functioning, quality of life, and health harms.

Safety capture

Prospective reporting should document cardiac measures, adverse events, co-exposures, discontinuations, and delayed complications rather than treating safety as background.

Comparators

Well-designed comparisons can help separate an intervention’s possible effects from expectancy, setting, time, concurrent care, and differences among participants.

Common questions

Keep the interpretation narrow.

Is ibogaine an approved treatment for opioid use disorder?

No. This map does not present ibogaine as an approved treatment. The human studies summarized here are limited in size and design, and safety concerns remain central to interpreting the findings.

Why are cardiac concerns relevant for every indication?

Cardiac risk is not limited to the condition being studied. QT changes, medication interactions, electrolyte disturbance, underlying disease, and polysubstance exposure can all alter the safety picture. The opioid evidence dossier examines how these issues intersect with the most studied indication.

What does “promising, nondefinitive” mean?

It means there are human signals worth studying further, but the evidence does not yet establish a reliable causal effect, an optimal protocol, or safety for any individual. The rating is about evidence maturity, not a recommendation.

Where should this evidence be placed alongside established care?

Evidence about ibogaine should not displace discussion of established, regulated options. For opioid use disorder, the National Institute on Drug Abuse’s overview of medications for opioid use disorder describes medications with a much more developed evidence and regulatory context.

A restrained conclusion

Useful evidence begins with its boundaries.

The present record is most developed for opioid use disorder and remains much less certain for other substance-use and behavioral-health questions. Across every indication, study limitations and safety considerations prevent this map from becoming a treatment directive.